Kenneth I. Moch is a Managing Director, Healthcare Investment Banking with ThinkEquity Partners in New York City, a 200 person boutique investment bank focused on providing financing and strategic advice to high-growth companies.
Mr. Moch has substantial experience in managing and financing advanced biomedical technologies, as an operating executive and as a strategist. As a senior biotechnology industry executive, he has been responsible for the completion of over 30 public offerings, private placements and corporate partnerships, many under difficult market and/or product development conditions.
Prior to joining ThinkEquity, Mr. Moch was Chairman, President & CEO of Alteon Inc., a company focused on small molecule therapeutics for cardiovascular aging and diabetic complications. He joined Alteon in February 1995 as Senior Vice President, Finance & Business Development and Chief Financial Officer. From 1990 to 1995, he served as President & CEO of Biocyte Corporation (now called PharmaStem), the cellular therapy company which pioneered the collection and use of cord blood stem cells as an alternative to bone marrow in transplantation therapy.
Prior to Biocyte, Mr. Moch was a founder and the Managing General Partner of Catalyst Ventures, a venture capital partnership focused on the creation of early stage biomedical and high-technology companies in the Baltimore-Washington region. From 1982 to 1988, he served as Vice President of The Liposome Company, Inc., a company developing a novel drug delivery technology for oncology and infectious diseases. Mr. Moch was a co-founder of the company and played a key role in all aspects of the company’s growth from a start-up research laboratory into a publicly held biopharmaceutical firm. From 1980 to 1982, Mr. Moch was a management consultant with McKinsey & Company, Inc. He previously was a biomedical technology consultant with Channing, Weinberg & Company, Inc. (The Wilkerson Group).
Mr. Moch has taken an active leadership role in the biotechnology industry. He is a member of the Governing Body of the Emerging Companies Section of the Biotechnology Industry Organization (BIO), where he Co-Chairs the Business Development Subcommittee. He is the immediate past Chairman of the Biotechnology Council of New Jersey (BCNJ) and a current member of the Board of the New York Biotechnology Association (NYBA), where he served on the Executive Committee from 2001 to 2005. Mr. Moch was Co-Chairman of the Executive Committee of BIO 2005, BIO’s annual international meeting, and is Chairman of the International Technology Transfer Advisory Committee of the Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences.
Mr. Moch received his A.B. in biochemistry from Princeton University, and an M.B.A. with emphasis in finance and marketing from the Stanford Graduate School of Business.
